Kenrik Industries Limited (BOM:544398)

G1 Therapeutics Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	9.93	10.61	4.74	3.88	3.71
Depreciation & Amortization	0.12	0.15	0.18	0.21	0.25
Other Operating Activities	-0.39	3.01	0.4	0.01	0.22
Change in Accounts Receivable	-15.61	24.04	0.28	-27.46	8.93
Change in Inventory	-26.2	-7.43	-30.16	15.07	-44.91
Change in Accounts Payable	5.02	-9.42	18.95	-32.26	25.5
Change in Other Net Operating Assets	1.82	2.73	8.46	-9.62	6.17
Operating Cash Flow	-25.32	23.69	2.86	-50.16	-0.14
Operating Cash Flow Growth	-	727.67%	-	-	-
Capital Expenditures	-	-	-	-0.14	-
Other Investing Activities	0.41	-	-	-	-
Investing Cash Flow	-2.35	0.71	-5.06	-0.14	-
Short-Term Debt Issued	-	2.12	2.16	2.25	-
Long-Term Debt Issued	2.86	-	-	-	0.15
Total Debt Issued	2.86	2.12	2.16	2.25	0.15
Net Debt Issued (Repaid)	2.86	2.12	2.16	2.25	0.15
Issuance of Common Stock	-	-	-	48	-
Financing Cash Flow	2.86	2.12	2.16	50.24	0.15
Net Cash Flow	-24.82	26.52	-0.04	-0.05	0.01
Free Cash Flow	-25.32	23.69	2.86	-50.3	-0.14
Free Cash Flow Growth	-	727.67%	-	-	-
Free Cash Flow Margin	-3.39%	3.35%	0.55%	-15.43%	-0.04%
Free Cash Flow Per Share	-2.80	2.63	0.32	-6.76	-0.03
Cash Income Tax Paid	4.9	0.57	1.37	1.3	1.3
Levered Free Cash Flow	-25.85	20.93	1.21	-51.5	-1.98
Unlevered Free Cash Flow	-25.83	20.93	1.21	-51.5	-1.98
Change in Working Capital	-34.98	9.93	-2.46	-54.27	-4.32

Source: S&P Global Market Intelligence. Standard template. Financial Sources.